JNNP: Early diagnosis of plasma and cerebrospinal fluid biomarkers in prions and their comparison with survival.

Early diagnosis and clinical management in patients with prion disease continue to face challenges, as changes in clinical manifestations overlap significantly with other clinical symptoms of rapidly developing dementia (RPD).
and there is a wide gap between the rate of disease progress and survival time.
prions include spontaneity, genetics and accessibility (medical origin, variability).
includes Kya's disease, Gerstmann-Strauss-Schneider disease (GSS), familial insomnia (FI) and volatile protease-sensitive prion disease (VPSPr).
is the most common prion virus, with different subsypes.
damage marked with cerebrospinal fluid (CSF) is not suitable for repeated measurements, disease and screening.
finding blood biomarkers is therefore a top priority.
: Blood and cerebrospinal fluid samples were analyzed and processed by the Neuropathology Laboratory of the Bologna Institute of Neuroscience.
selected a total of 442 cases, including 336 cases of prion (193 with two organisms available at the same time, 125 with cerebrospinal fluid and 18 with blood only) and 106 cases of rapidly developing dementia.
, 37 healthy control or tension-type headache patients were analyzed.
EDTA plasma samples are collected in accordance with standard procedures, equally divided and stored at -80 degrees C.
we did all the blood analysis on the SiMOA SR-X analyzer platform (Quanterix, Bieleica, Massachusetts, USA).
plasma tau and NfL are measured using SiMOA Human t-tau and SiMOA NF-light advantage kits, respectively.
in-measurement and inter-measurement variation coefficients (CVs) for tau were 7.1% and 11.2%, respectively, and NfL was 3.7% and 9.2%, respectively.
results: Age was associated with plasma nerve wire light chain protein (NfL) levels, independent of other blood and CSF biomarkers, in two groups of patients (all RPD cases, r s 0.181, p s 0.006) and in control (r s 0.706, p s 0.003, n s 38).
differences had no effect on blood and CSF biomarker value.
compared to the control group, plasma tau and NfL levels were higher in patients with the virus (both comparisons were p-lt;0.001; NfL age-corrected linear regression?0.810, p-lt;0.001).
tau and NfL levels in the plasma of patients with np-RPD were higher than in the control group (tau p s 0.044; NfL p s.lt;0.001; NfL age-adjusted linear regression s.0.599, p slt;0.001).
plasma biomarkers (tau and NfL) are not as good as conventional cerebrospinal fluid markers in diagnosing prion diseases.
Abu-Rumeileh S, Baiardi S, Ladogana A, et al Comparison between plasma and cerebrospinal fluid biomarkers for the early diagnosis and association survival with prion disease Journal of Neurology, Neurosurgery and Psimology Published Online First:14 September 2020. doi: 10.1136/jnnp-2020-323826MedSci Original Source: MedSci Original Copyright Notice: All noted on this website "Source: Met Medical" or "Source: MedSci Original" text, Images and audio-visual materials, copyrighted by Metz Medical, are not authorized to be reproduced by any media, website or individual and must be reproduced with the reference "Source: Metz Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
reproduce content at the same time does not represent the position of this site.
leave a message here.